Development of a novel BAFF responsive cell line suitable for detecting bioactive BAFF and neutralizing antibodies against BAFF-pathway inhibiting therapeutics

Cells

Volumn 3, Issue 1, 2014, Pages 79-91

  Hu, Jenny ^a   Yu, Yanbin ^a   Han, Hong ^a   Civoli, Francesca ^a   Zhuang, Yao ^a   Thomas, John ^a   Swanson, Steve ^a   Jing, Shuqian ^b   Gupta, Shalini ^a  

^a AMGEN INC   (United States)

^b GMAX Biopharm   (China)

Author keywords

BAFF response; COS 1 cell line; Hybrid receptor; Neutralizing antibody detection; Serum matrix; Transfection

Indexed keywords

B CELL ACTIVATING FACTOR; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; BIOASSAY; CELL LINE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION;

EID: 84940462733     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells3010079     Document Type: Article

References (28)

1. Mackay, F.; Browning, J.L. BAFF: A fundamental survival factor for B-cells. Nat. Rev. Immunol. 2002, 2, 465-475.
2. Gordon, N.C.; Pan, B.; Hymowitz, S.G.; Yin, J.; Kelley, R.F.; Cochran, A.G.; Yan, M.; Dixit, V.M.; Fairbrother, W.J.; Starovasnik, M.A. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry 2003, 42, 5977-5983.
3. Cheema, G.S.; Roschke, V.; Hilbert, D.M.; Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44, 1313-1319.
4. Matsushita, T.; Hasegawa, M.; Yanaba, K.; Kodera, M.; Takehara, K.; Sato, S. Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006, 54, 192-201.
5. Zhang, J.; Roschke, V.; Baker, K.P.; Wang, Z.; Alarcón, G.S.; Fessler, B.J.; Bastian, H.; Kimberly, R.P.; Zhou, T. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001, 166, 6-10.
6. Stohl, W. A therapeutic role for BLyS antagonists. Lupus 2004, 13, 317-322.
7. Wallace, D.J.; Stohl, W.; Furie, R.A. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61, 1168-1178.
8. Tak, P.P.; Thurlings, R.M.; Rossier, C. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeateddose study. Arthritis Rheum. 2008, 58, 61-72.
9. Kreuzaler, M.; Rauch, M.; Salzer, U.; Birmelin, J.; Rizzi, M.; Grimbacher, B.; Plebani, A.; Lougaris, V.; Quinti, I.; Thon, V.; et al Soluble BAFF levels inversely correlate with peripheral B-cell numbers and the expression of BAFF receptors. J. Immunol 2012, 188, 497-503.
10. Molica, S.; Digiesi, G.; Battaglia, C. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur. J. Haematol. 2010, 85, 314-320.
11. Lahiri, A.; Pochard, P.; Le Pottier, L. The complexity of the BAFF TNF-family members: implications for autoimmunity. J. Autoimmun. 2012, 39, 189-198.
12. Day, E.S.; Cachero, T.G.; Qian, F. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005, 44, 1919-1931.
13. Morrison, M.D.; Reiley, W.; Zhang, M.; Sun, S.C. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B-cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J. Biol. Chem. 2005, 280, 10018-10024.
14. Yang, M.; Hase, H.; Legarda-Addison, D.; Varughese, L.; Seed, B.; Ting, A.T. B-cell maturation antigen, the receptor for a proliferation-inducing ligand and B-cell-activating factor of the TNF family, induces antigen presentation in B-cells. J. Immunol. 2005, 175, 2814-2824.
15. McClements, M.; Williams. S.; Ball, C.; Bristow, A.; Wadhwa, M.; Meager, A. A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells. J. Immunol. Methods 2008, 337, 63-70.
16. Thompson, J.S.; Bixler, S.A.; Qian, F. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293, 2108-2111.
17. Miller, D.J.; Hayes, C.E. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol. 1991, 21, 1123-1130.
18. Schiemann, B.; Gommerman, J.L.; Vora, K. An essential role for BAFF in the normal development of B-cells through a BCMA-independent pathway. Science 2001, 293, 2111-2114.
19. Aggarwal, B.B. Signaling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 2003, 3, 745-756.
20. Chen, Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell. Biol. 2005, 7, 758-765.
21. Kim, S.H.; Reznikov, L.L.; Stuyt, R.J. Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain. J. Immunol. 2001, 166, 148-154.
22. Banner, D.W.; D'Arcy, A.; Janes, W. Crystal structure of the soluble human 55 kd TNF receptorhuman TNF beta complex: Implications for TNF receptor activation. Cell 1993, 73, 431-445.
23. Fantl, W.J.; Johnson, D.E.; Williams, L.T. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 1993, 62, 453-481.
24. Adam, D.; Kessler, U.; Krönke, M. Cross-linking of the p55 tumor necrosis factor receptor cytoplasmic domain by a dimeric ligand induces nuclear factor-kappa B and mediates cell death. J. Biol. Chem. 1995, 270, 17482-17487.
25. Bazzoni, F.; Alejos, E.; Beutler, B. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Proc. Natl. Acad. Sci. USA 1995, 92, 5376-5380.
26. Boldin, M.P.; Mett, I.L.; Varfolomeev, E.E. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem. 1995, 270, 387-391.
27. Gavin, A.L.; Aït-Azzouzene, D.; Ware, CF.; Nemazee, D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B-cell survival cytokine, BAFF. J. Biol. Chem. 2003, 278, 38220-38228.
28. Casadevall, N.; Nataf, J.; Viron, B.; Kolta, A.; Kiladjian, J.J.; Martin-Dupont, P.; Michaud, P.; Papo, T.; Ugo, V.; Teyssandier, I.; et al Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346, 469-475.